Healthcare / Medical DevicesShenzhen
$9.40
+0.53 (+5.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $606.3M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
58.8x
↑EV/EBITDA
22.2x
↑ROE
2.7%
↑Gross Margin
10.6%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.2%
FCF CAGR
+44.5%
FCF margin
9.2%
FCF / Net income
9.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.99B · net income $68.2M · FCF $646.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.99B | $6.99B | $7.35B | $7.48B | $6.36B |
| Net Income | $68.2M | $68.2M | $130.7M | $153.9M | $124.9M |
| EBITDA | $224.0M | $224.0M | $362.0M | $426.8M | $636.1M |
| EPS | 0.14 | 0.14 | 0.28 | 0.36 | 0.31 |
| Gross Margin | 10.6% | 10.6% | 10.8% | 11.7% | 13.2% |
| Operating Margin | 3.0% | 3.0% | 3.4% | 4.5% | 5.8% |
| Net Margin | 1.0% | 1.0% | 1.8% | 2.1% | 2.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.59 | 0.56 | 1.87 |
| Current Ratio | 1.53 | 1.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $646.0M | $646.0M | $606.3M | $562.4M | $214.1M |
| Returns | |||||
| ROE | 2.7% | 2.7% | 5.3% | 6.3% | 8.6% |
| Valuation | |||||
| P/E | 58.75 | 58.75 | 36.07 | 44.44 | — |
| EV/EBITDA | 22.24 | 22.24 | 15.12 | 18.04 | — |
| P/B | 1.83 | 1.83 | 1.90 | 2.79 | — |
| Growth & Yield | |||||
| Revenue Growth | -4.9% | -4.9% | -1.8% | 17.7% | — |
| EPS Growth | -50.0% | -50.0% | -22.2% | 16.1% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
81.3%
EPS terminal req.
$0.83
Spread vs growth
-131.3%
5Y implied EPS CAGR
48.4%
EPS terminal req.
$1.01
Spread vs growth
-98.4%
10Y implied EPS CAGR
27.8%
EPS terminal req.
$1.63
Spread vs growth
-77.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
36.8x → 68.4x
EPS bridge
0.28 → 0.14
Residual
-42.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.